Janet Woodcock continues to remind regulators that their manufacturing assessments have a lot in common and can converge around one global dossier.
Woodcock Touts Baby Steps Toward Global Manufacturing Quality Dossier
Focus of the campaign is the well-established pharmaceutical manufacturing sector, rather than cell and gene therapy production, the US FDA’s principal deputy commissioner said.
